The value of choosing the “right” indication for phase 2a

Even if your company is not planning to develop a pipeline asset through phase 3, you’re significantly more likely to secure a favorable deal with a pharma partner if you deliver relevant phase 2a data in a commercially viable indication. … Continue reading

The value of developing a good TPP for your product in early development

There have recently been a number of articles in biopharma publications and social media suggesting that the target product profile (or TPP) is an enemy of innovation and and reduces productivity in the industry.  The authors of these articles suggest … Continue reading